AMRS News and Press, Amyris Inc. From 03/01/22

Amyris press release (NASDAQ:AMRS): Q4 GAAP EPS of -$0.43 misses by $0.23. Revenue of $64.78M (-18.7% Y/Y) beats by $10.15M. For further details see: Amyris GAAP EPS of -$0.43 misses by $0.23, revenue of $64.78M beats by $10.15M

AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS - 2021 full year total revenue grew 97% year-over-year to $342 million - Q4 and full year 2021 consumer revenue +86% and +78% respectively versus prior year - Accelerating consumer growth and new pa...

Amyris (NASDAQ:AMRS) is scheduled to announce Q4 earnings results on Tuesday, Mar. 1, before market open. The consensus EPS estimate is -$0.16 (-433.3% Y/Y) and the consensus revenue estimate is $54.63M (-31.5% Y/Y). Over the last 2 years, AMRS has beaten EPS estimates 25% of the time and has...

ADT,AGEN,AKBA,ALBO,AMRN,AMRS,AXSM,AZO,OTCPK:BAYZF,BIDU,BLDR,BMO,BNS,BSY,CCCS,CHS,CMRX,CRON,DPZ,EHTH,EPZM,EVRI,FOUR,OTCQX:GTBIF,HGV,HOV,HRL,HTA,HZNP,IGT,IQ,ITCI,KSS,KTB,LILM,MANU,MCRB,MLCO,NFE,OTCQB:NLST,NUWE,OKE,PIRS,PLTK,PRGO,QTRX,REGI,RYTM,SE,SJM,TGT,TGTX,TLS,TWNK,UWMC,VFF,VRTV,WEN,WKHS,XXI...

AMYRIS TO PRESENT AT THE 42nd ANNUAL COWEN HEALTH CARE CONFERENCE PR Newswire EMERYVILLE, Calif. , Feb. 28, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable cons...

AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 1 PR Newswire EMERYVILLE, Calif. , Feb. 22, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's tr...

AMYRIS CLOSES ECOFABULOUS TRANSACTION, AND COMMENCES PRODUCTION OF CONSUMER PRODUCTS IN RENO, NEVADA PLANT PR Newswire EMERYVILLE, Calif. , Feb. 9, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world'...

The Synthetic Biology sector underperformed the overall market in Q4 2021. Temporary supply chain disruptions drove the bulk of revenue headwinds. Convertible Debt Offering and Tax Loss Harvesting led to extreme Short Selling and are now behind the company. Early January 2022 ...

AMYRIS ANNOUNCES APPOINTMENT OF ANA DUTRA TO BOARD OF DIRECTORS PR Newswire EMERYVILLE, Calif. , Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption thro...

Last year was a big year for the stock market. Broader exchanges reached record levels with some of the most bullish optimism in recent history. Thanks to reopening efforts, new vaccines, and a strengthening economy, investors shrugged off inflation and rate-hike fears in exchange for stock...